Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Category

Hematology Oncology

The Hematology/Oncology Conference is moderated by Robert G. Lerner, M.D., Professor of Medicine at New York Medical College.

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

More

Emerging Treatments In Acute Myeloid Leukemia (AML)

This program will discuss several investigational agents for the treatment of AML. Acute myeloid leukemia (AML) is a relatively uncommon but difficult-to-treat hematologic malignancy. AML is defined by the World Health… Organization (WHO) as the presence of 20% or greater myeloblasts and/or monoblasts/promonocytes and/or megakaryoblasts in the blood or bone marrow, or the localized accumulation of myeloid blasts in tissues (??oemyeloid sarcoma???); in some cases associated with specific cytogenetic abnormalities, the diagnosis can be made regardless of the blast count. …
Authors: Mary-Elizabeth M. Percival, M.D., M.S. and Roland B. Walter, M.D., Ph.D., M.S.
Estimated Time: 1 Hour
View Course
More

More More

Robert G. Lerner, M.D.

Hematology Oncology

Dr. Robert G. Lerner, Cyberounds® Hematology/Oncology moderator, is Professor and Vice Chairman, Department of Medicine and Professor of Pathology at New York Medical College and is board certified in both …hematology and medical oncology. A Phi Beta Kappa graduate of NYU and its medical school, Bob did his postgraduate training at Bellevue, Montefiore Hospital and USC. He is a recipient of an NIH Research Career Development Award and is Chief, Hematology, Westchester County Medical Center. Thromboembolic disease and the control of coagulation are Dr. Lerner's major areas of research interest.

Within the past 12 months, Dr. Lerner has received research/grant support from Sanofi-Aventis and Boehringer Ingelheim, and been on the Speakers Bureau for Eisai, GlaxoSmithKline and Sanofi-Aventis.

Last Update: 2/21/2021

More More

More Hematology/Oncology Courses

AML2

Estimated Time: 6 Hours
View Course
More

Pro-State Challenge 2

Estimated Time: 6 Hours
View Course
More

Unexplained Bleeding in Hospitalized Patients

This presentation may include discussion of commercial products and services. A 65-year-old man is hospitalized for cerebellar infarction. At admission, he was drowsy, without clinical evidence of bleeding. He… was administered aspirin, clopidogrel and valproate for cerebellar infarction; a statin for hyperlipidemia; and clindamycin and teicoplanin for aspiration pneumonia. Following intubation, a tracheostomy was performed. Bleeding history: No previous familial medical history of bleeding or coagulopathy; no clinical symptoms or signs of malignancy, antiphospholipid syndrome or collagen vascular disease. Initial laboratory…
Authors: Meera B. Chitlur, M.D.
Estimated Time: 1 Hour
View Course
More

Lung Cancer Chemoprevention

Lung cancer is now the leading cause of cancer death in both men and women in the United States, as well as the leading cause of cancer death worldwide. … The 5-year U.S. survival rate for lung cancer is a discouraging 16%, and while there has been an interval improvement in survival, the survival advances realized in other common malignancies have not translated to lung cancer. One reason for the discouraging survival statistics is that the majority of patients present…
Authors: Robert L. Keith, M.D.
Estimated Time: 1 Hour
View Course
More

Molecularly Targeted Therapy for Malignant Brain Tumors

Gliomas are the most frequently occurring malignant primary brain tumors and include astrocytomas, oligodendrogliomas and ependymomas. Combined, these histologies account for approximately 40% of all primary brain tumors and over… 80% of all malignant CNS tumors. Typically, high−grade gliomas (Grades III and IV) are referred to as “malignant” glioma. As glioblastoma (GBM), the only grade IV glioma, accounts for approximately 50% of gliomas, a majority of glioma research has focused on this tumor type (see Figure…
Authors: Nicole A. Shonka, M.D., and Mark R. Gilbert, M.D.
Estimated Time: 1 Hour
View Course
More

Anti-EGFR Therapy: Incidence, Pathology and Management of Associated Side Effects

The severity of EGFR-related dermatological adverse events is graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (Table 1). EGFR is expressed widely in human… tissue including the epidermis, sweat gland apparatus and the hair follicle epithelium. , , The cutaneous reactions to EGFR inhibitors include follicular eruptions, generalized xerosis, pruritis, hyperpigmentation, panniculitis, paronychia, alopecia, trichomegaly, fine brittle hair, ocular irritation and vaginal dryness (Table 2). Current data suggest that skin eruption in patients taking…
Authors: Sunil Babu, M.D., Michael Liu, M.D., and Robert G. Lerner, M.D.
Estimated Time: 1 Hour
View Course
More